(HOWL) Werewolf Therapeutics - Ratings and Ratios
Immunotherapy, Oncology, Solid Tumors, Lymphoma, Autoimmune
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 104% |
| Value at Risk 5%th | 145% |
| Relative Tail Risk | -14.87% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.39 |
| Alpha | -78.64 |
| CAGR/Max DD | -0.19 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.613 |
| Beta | 2.114 |
| Beta Downside | 2.400 |
| Drawdowns 3y | |
|---|---|
| Max DD | 92.04% |
| Mean DD | 53.68% |
| Median DD | 54.52% |
Description: HOWL Werewolf Therapeutics October 19, 2025
Werewolf Therapeutics, Inc. (NASDAQ: HOWL) is a U.S. biotech focused on engineering “INDUKINE” cytokine therapeutics that are conditionally activated to boost both adaptive and innate immunity, aiming to overcome the toxicity and efficacy limits of traditional pro-inflammatory cancer immunotherapies.
The firm’s flagship pipeline includes WTX-124 (a conditionally activated IL-2) and WTX-330 (a conditionally activated IL-12), both targeted at advanced or metastatic solid tumors, with additional candidates such as JZP898 (IFN-α), WTX-921 (IL-10 for inflammatory bowel disease), WTX-712 (IL-21) and WTX-518 (IL-18) in pre-clinical or early IND stages.
Key quantitative signals as of the most recent 10-Q (Q2 2024) show roughly $48 million in cash and short-term investments, providing an estimated 12-month runway at current burn rates; the company raised $30 million in a February 2024 private placement at a $300 million post-money valuation, indicating investor confidence despite the high-risk, early-stage profile. The broader immuno-oncology market is projected to grow at a CAGR of ~13 % through 2030, driven by expanding indications for cytokine-based therapies and increasing payer acceptance of targeted immune modulators.
For a deeper, data-driven view of HOWL’s valuation dynamics and risk-adjusted upside, you may find the analyst tools on ValueRay worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income (-72.8m TTM) > 0 and > 6% of Revenue (6% = 113.1k TTM) |
| FCFTA -0.80 (>2.0%) and ΔFCFTA -46.47pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 2683 % (prev 3300 %; Δ -617.7pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.80 (>3.0%) and CFO -63.5m > Net Income -72.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 3.87 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (45.8m) change vs 12m ago 4.80% (target <= -2.0% for YES) |
| Gross Margin 32.41% (prev 46.67%; Δ -14.25pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 1.72% (prev 2.45%; Δ -0.74pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -15.28 (EBITDA TTM -66.7m / Interest Expense TTM 4.47m) >= 6 (WARN >= 3) |
Altman Z'' -28.94
| (A) 0.64 = (Total Current Assets 68.2m - Total Current Liabilities 17.6m) / Total Assets 79.6m |
| (B) -5.87 = Retained Earnings (Balance) -467.0m / Total Assets 79.6m |
| warn (B) unusual magnitude: -5.87 — check mapping/units |
| (C) -0.62 = EBIT TTM -68.4m / Avg Total Assets 109.8m |
| (D) -9.34 = Book Value of Equity -467.0m / Total Liabilities 50.0m |
| Total Rating: -28.94 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 32.81
| 1. Piotroski 0.50pt |
| 2. FCF Yield data missing |
| 3. FCF Margin data missing |
| 4. Debt/Equity 1.26 |
| 5. Debt/Ebitda 0.43 |
| 6. ROIC - WACC (= -77.85)% |
| 7. RoE -144.4% |
| 8. Rev. Trend -46.97% |
| 9. EPS Trend 34.29% |
What is the price of HOWL shares?
Over the past week, the price has changed by +14.52%, over one month by -38.27%, over three months by -28.06% and over the past year by -50.00%.
Is HOWL a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the HOWL price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.2 | 517% |
| Analysts Target Price | 6.2 | 517% |
| ValueRay Target Price | 0.9 | -11% |
HOWL Fundamental Data Overview November 25, 2025
P/S = 52.2151
P/B = 1.4349
Beta = 0.727
Revenue TTM = 1.89m USD
EBIT TTM = -68.4m USD
EBITDA TTM = -66.7m USD
Long Term Debt = 21.7m USD (from longTermDebt, last quarter)
Short Term Debt = 7.50m USD (from shortTermDebt, last quarter)
Debt = 37.3m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -28.4m USD (from netDebt column, last quarter)
Enterprise Value = 14.0m USD (42.4m + Debt 37.3m - CCE 65.7m)
Interest Coverage Ratio = -15.28 (Ebit TTM -68.4m / Interest Expense TTM 4.47m)
FCF Yield = -455.4% (FCF TTM -63.6m / Enterprise Value 14.0m)
FCF Margin = -3376 % (FCF TTM -63.6m / Revenue TTM 1.89m)
Net Margin = -3864 % (Net Income TTM -72.8m / Revenue TTM 1.89m)
Gross Margin = 32.41% ((Revenue TTM 1.89m - Cost of Revenue TTM 1.27m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.18 (Enterprise Value 14.0m / Total Assets 79.6m)
Interest Expense / Debt = 1.73% (Interest Expense 644.0k / Debt 37.3m)
Taxrate = 21.0% (US default 21%)
NOPAT = -54.0m (EBIT -68.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.87 (Total Current Assets 68.2m / Total Current Liabilities 17.6m)
Debt / Equity = 1.26 (Debt 37.3m / totalStockholderEquity, last quarter 29.6m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -28.4m / EBITDA -66.7m)
Debt / FCF = 0.45 (negative FCF - burning cash) (Net Debt -28.4m / FCF TTM -63.6m)
Total Stockholder Equity = 50.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -91.48% (Net Income -72.8m / Total Assets 79.6m)
RoE = -144.4% (Net Income TTM -72.8m / Total Stockholder Equity 50.4m)
RoCE = -94.82% (EBIT -68.4m / Capital Employed (Equity 50.4m + L.T.Debt 21.7m))
RoIC = -69.87% (negative operating profit) (NOPAT -54.0m / Invested Capital 77.3m)
WACC = 7.98% (E(42.4m)/V(79.7m) * Re(13.81%) + D(37.3m)/V(79.7m) * Rd(1.73%) * (1-Tc(0.21)))
Discount Rate = 13.81% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 11.91%
Fair Price DCF = unknown (Cash Flow -63.6m)
EPS Correlation: 34.29 | EPS CAGR: 77.47% | SUE: 0.36 | # QB: 0
Revenue Correlation: -46.97 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
Additional Sources for HOWL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle